Abstract: Disclosed is a composition and a method for the prevention or treatment of diabetic complications, which includes C-peptide bound to elastin-like polypeptide (ELP) and is thus capable of effectively preventing or treating diseases resulting from hyperglycemia, which is a major cause of diabetes, for example, diabetic retinopathy, and the like.

Abstract: Disclosed is a method of measuring protein kinase activity, including a) attaching GMBS (N-[?-maleimidobutyryloxy]sulfosuccinimide ester) to a base plate, b) attaching a substrate that reacts with a protein kinase to the base plate having GMBS attached thereto, thus manufacturing a kit for measuring protein kinase activity, c) introducing, to the kit, a mixture of a sample to be analyzed and a buffer including triton X-100, and d) probing phosphorylation of the substrate caused by the protein kinase contained in the sample, thereby measuring the activity of the protein kinase.

Abstract: Disclosed is a composition for the prevention or treatment of diabetic complications, containing a benzodiazepine-based compound, thereby effectively preventing or treating diseases resulting from hyperglycemia, which is the leading cause of diabetes, especially diseases caused by vascular leakage.

Abstract: Disclosed is a composition and a method for the prevention or treatment of diabetic complications, which includes C-peptide bound to elastin-like polypeptide (ELP) and is thus capable of effectively preventing or treating diseases resulting from hyperglycemia, which is a major cause of diabetes, for example, diabetic retinopathy, and the like.

Abstract: Disclosed is a composition for diagnosing cancer, including an agent for measuring PKA (Protein Kinase A) activity.

Abstract: Disclosed is a composition for the prevention or treatment of diabetic complications, containing a benzodiazepine-based compound, thereby effectively preventing or treating diseases resulting from hyperglycemia, which is the leading cause of diabetes, especially diseases caused by vascular leakage.

Abstract: Disclosed is a composition for the prevention or treatment of diabetic complications, containing a benzodiazepine-based compound, thereby effectively preventing or treating diseases resulting from hyperglycemia, which is the leading cause of diabetes, especially diseases caused by vascular leakage.

Abstract: Disclosed is a composition for the prevention or treatment of diabetic complications, containing a benzodiazepine-based compound, thereby effectively preventing or treating diseases resulting from hyperglycemia, which is the leading cause of diabetes, especially diseases caused by vascular leakage.

Abstract: Disclosed are a pharmaceutical composition and a method for preventing or treating diabetic complications caused by vascular leakage, comprising a TGase2 inhibitor, and a method of screening a preventive or therapeutic agent for diabetic complications caused by vascular leakage.

Abstract: Disclosed are a pharmaceutical composition and a method for preventing or treating diabetic complications caused by vascular leakage, comprising a TGase2 inhibitor, and a method of screening a preventive or therapeutic agent for diabetic complications caused by vascular leakage.

Abstract: Disclosed is a method of measuring protein kinase activity, including a) attaching GMBS (N-[?-maleimidobutyryloxy]sulfosuccinimide ester) to a base plate, b) attaching a substrate that reacts with a protein kinase to the base plate having GMBS attached thereto, thus manufacturing a kit for measuring protein kinase activity, c) introducing, to the kit, a mixture of a sample to be analyzed and a buffer including triton X-100, and d) probing phosphorylation of the substrate caused by the protein kinase contained in the sample, thereby measuring the activity of the protein kinase.

Abstract: Disclosed is a composition for diagnosing cancer, including an agent for measuring PKA (Protein Kinase A) activity.

Abstract: Disclosed is a method for the prevention or treatment of vascular leakage-induced diseases and diabetic retinopathy, using C-peptide. Found to prevent extravacular leakage by inhibiting VEGF-induced disassembly of VE-cadherin, C-peptide can be applied to the prevention or treatment of various diabetic complications accompanied by vascular leakage.

Abstract: Disclosed are a method and composition for the prevention or treatment of diabetic angiogenesis impairment or diabetic wound-healing impairment, using C-peptide. Found to be able to induce angiogenesis through chemotactic migration of endothelial cells, cell migration to wounded areas, capillary-like network formation, and extracellular signal-regulated kinases 1/2 and Akt phosphorylation and nitric oxide production, C-peptide has prophylactic or therapeutic applications in a broad spectrum of various diabetic complications including diabetic angiogenesis impairment.

Abstract: Disclosed is a method for the prevention or treatment of vascular leakage-induced diseases and diabetic retinopathy, using C-peptide. Found to prevent extravascular leakage by inhibiting VEGF-induced disassembly of VE-cadherin, C-peptide can be applied to the prevention or treatment of various diabetic complications accompanied by vascular leakage.

Abstract: Disclosed are a method and a composition for the prevention or treatment of diabetic angiogenesis impairment or diabetic wound-healing impairment, using C-peptide. Found to be able to induce angiogenesis through chemotatic migration of endothelial cells, cell migration to wounded areas, capillary-like network formation, and ERK1/2 and Akt phosphorylation and NO production, C-peptide has prophylactic or therapeutic applications in a broad spectrum of various diabetic complications including diabetic angiogenesis impairment.